PT - JOURNAL ARTICLE AU - Shao, Pei-Lan AU - Tu, Hsiao-Chen AU - Gong, Yu-Nong AU - Shu, Hung-Yu AU - Kirby, Ralph AU - Hsu, Li-Yun AU - Yeo, Hui-Yee AU - Kuo, Han-Yueh AU - Huang, Yi-Chia AU - Lin, Yung-Feng AU - Weng, Hui-Ying AU - Wu, Yueh-Lin AU - Chen, Chien-Chih AU - Chen, Tzen-Wen AU - Lee, Kuo-Ming AU - Huang, Chung-Guei AU - Shih, Shin-Ru AU - Chen, Wei J AU - Wu, Chen-Chi AU - Yu, Chong-Jen AU - Tsai, Shih-Feng TI - Emergence and Persistent Dominance of Omicron BA.2.3.7 Variant in Community Outbreaks in Taiwan AID - 10.1101/2022.09.27.22280238 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.27.22280238 4099 - http://medrxiv.org/content/early/2022/09/27/2022.09.27.22280238.short 4100 - http://medrxiv.org/content/early/2022/09/27/2022.09.27.22280238.full AB - Using high-throughput sequencing of the SARS-CoV-2 genome, we have analyzed 2405 PCR-positive swab samples from 2339 individuals and identified the Omicron BA.2.3.7 variant as a major lineage of the recent community outbreak in Taiwan. Since April 2022, a series of new waves of Omicron cases have surfaced in Taiwan and spread throughout the island. We conducted genomic surveillance with a high success rate and have submitted 1966 full-length Omicron sequences to GISAID. This has permitted identification of signature amino acid changes (ORF1a:L631F, S:K97E, N:M322I) in 1584 (80.6%) of the translated SARS-CoV-2 sequences. The newly established BA.2.3.7 lineage, which is relatively common in Asian countries, is now persistently present in Taiwan. By June 2022 this dominant strain had established a substantial existence in the sequence pool, resulting in additional mutations. The rapid spread and expansion of the Omicron BA.2.3.7 lineage in Asia has had an important socioeconomic impact on health policy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Ministry of Health and Welfare of Taiwan (MOHW110-TDU-C-222-000010) to S.F.T., by the Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) of Taiwan, the National Science and Technology Council (NSTC), Taiwan (NSTC 111-2321-B-182-001, 111-2634-F-182-001, and 111-2221-E-182-053-MY3), and the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number 5U01AI151698-02 to Y.N.G. and S.R.SAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of National Taiwan University Hospital Hsin-Chu Branch gave 110-110-E ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors